AIHealthcare

Exact Sciences Corporation is a Madison, Wisconsin–based molecular diagnostics company focused on cancer screening, early detection, recurrence-risk assessment, treatment guidance, and disease monitoring. Its principal products and platforms include Cologuard colorectal-cancer screening, Oncotype DX genomic tests, and additional molecular diagnostic programs such as molecular residual disease, multi-cancer early detection, and hereditary cancer-risk assessment. The company is a major commercial provider of cancer screening and precision-oncology diagnostics rather than a pure-play artificial-intelligence company; the available company materials emphasize molecular testing, genomics, clinical evidence, and data-driven diagnostics, with no clearly documented standalone AI product or AI-specific financing. Exact Sciences reported approximately $3.25 billion in 2025 revenue and more than 5.5 million cancer test results in 2025. In November 2025, Abbott announced a definitive agreement to acquire Exact Sciences for $105 per share in cash, representing approximately $21 billion of equity value and approximately $23 billion of enterprise value; the announcement stated that closing was expected in the second quarter of 2026, subject to approvals and customary conditions.